Efficacy and safety of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis in a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study
In this medfyle
Expert commentary by Siba P Raychaudhuri, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ACR Convergence 2020 and presented by:
Philip Mease, MD
Seattle Rheumatology Associates, PLLC
Seattle, WA, USA
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Siba P Raychaudhuri, MD
Professor, Rheumatology and Dermatology
University of California Davis, CA, USA
The content is produced by Infomedica, an approved ACR education partner. The summary text was drafted by Marie Farrow, and reviewed by Alessia Alunno, MD, PhD, an independent external expert, and approved by Atul Deodhar, MD, MRCP, the scientific editor of the program.
This activity is included in the ACR's Education Partner program. Independent reporting and the viewpoints expressed are those of Infomedica and its affiliates and do not represent the ACR.
About the Expert
Siba P Raychaudhuri, MD
Professor, Rheumatology and Dermatology
University of California Davis, CA, USA
Siba Raychaudhuri is Professor of Rheumatology and Dermatology, Director of the Psoriasis and Psoriatic arthritis Clinic, Chief of Rheumatology at the VA Medical Center, Sacramento, and Program Director Rheumatology at UC Davis.